Biogen has entered a collaboration with Stoke Therapeutics to develop and and commercialise zorevunersen to treat Dravet ...

Under terms of the deal, Stoke will spearhead global development of zorevunersen, while Biogen will receive exclusive rights ...

Discover Stoke Therapeutics' innovative RNA-based treatments like zorevunersen for Dravet syndrome, with a promising pipeline ...

AAV-Navβ1 gene therapy effectively reduces seizures and prolongs life in a mouse model of SCN1B-linked Dravet syndrome, ...

Biogen ( NASDAQ: BIIB) and Stoke Therapeutics ( NASDAQ: STOK) said on Tuesday they are collaborating to develop and ...

Biogen and Stoke Therapeutics have announced a partnership aimed at advancing a disease-modifying treatment for Dravet ...

In exchange for $165 million, Biogen now has access to zorevunersen, a potential first-of-its-kind treatment for Dravet ...

Biogen has bolstered its pipeline by licensing ex-US rights to a drug for Dravet syndrome – a rare form of epilepsy – from ...

The deal, which features up to $385 million in milestones, gives Biogen exclusive rights to commercialize Stoke’s ...

A team of researchers has developed a new gene therapy for children with Dravet syndrome - a rare type of epilepsy in ...

Biogen has entered a collaboration with Stoke Therapeutics to develop and and commercialise zorevunersen to treat Dravet syndrome in all territories outside Canada, Mexico and the US. Dravet ...

Biogen and Stoke Therapeutics have signed a deal to co-develop and sell Stoke’s experimental drug for Dravet syndrome, ...